SCHEMBL20969718

SCHEMBL20969718

COc1ccc(CCN(Cc2ccc(C(=O)O)cc2)c2nc3cccc(F)c3s2)cc1F

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 1/20 0.55
TAS2R14 Q9NYV8 1/20 0.44
ACHE P22303 1/20 0.43
MEP1B Q16820 1/20 0.42
PTGER4 P35408 1/20 0.42
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
LPAR1 Q92633 7/20 0.41
LPAR5 Q9H1C0 7/20 0.41
ALOX5 P09917 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALKBH1 Q13686 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20969613 0.95 KARS1 (0.55) KARS1TAS2R14ALDH1A1LPAR1LPAR5
SCHEMBL20969653 0.93 KARS1 (0.53) KARS1TAS2R14ACHEALDH1A1LPAR1
SCHEMBL20969610 0.92 KARS1 (0.53) KARS1TAS2R14ACHEPTGER4ALDH1A1
SCHEMBL20969724 0.92 KARS1 (0.53) KARS1TAS2R14ACHEMEP1BALDH1A1
SCHEMBL20969699 0.91 KARS1 (0.53) KARS1TAS2R14ALDH1A1LPAR1LPAR5
SCHEMBL20969735 0.90 KARS1 (0.51) KARS1TAS2R14ACHEMEP1BPTGER4
SCHEMBL20969601 0.90 KARS1 (0.59) KARS1TAS2R14ALDH1A1LPAR1LPAR5
SCHEMBL20969682 0.88 KARS1 (0.70) KARS1TAS2R14RAB9ALPAR1LPAR5
SCHEMBL20969642 0.88 KARS1 (0.56) KARS1TAS2R14ALDH1A1LPAR1LPAR5
SCHEMBL20969636 0.88 KARS1 (0.53) KARS1TAS2R14ALDH1A1LPAR1LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP claimed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US claimed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US claimed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP claimed
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP disclosed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US disclosed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US disclosed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same ILK, SBDS, BDKRB1 KARS1 6/4885TAS2R14 1971/4885ACHE 4824/4885
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same ILK, SBDS, BDKRB1 KARS1 6/4885TAS2R14 1971/4885ACHE 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.